Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan
DOI:
https://doi.org/10.2478/amb-2024-0005Keywords:
SARS-CoV-2 N protein, COVID-19, SARS-CoV-2Abstract
The spread of SARS-CoV-2 represented a global health crisis. On May 5, 2023, the chief of the World Health Organization (WHO) officially announced the end of COVID-19 as a global health emergency. Serological assays can identify previously infected SARS-CoV-2 individuals, even if they did not go for testing while acutely ill. The current study sought to detect antibodies directed against the nucleocapsid of SARS-CoV-2 (IgG against the SARS-CoV-2 N protein) in both vaccinated and unvaccinated COVID-19 individuals. Of the 100 participants, 53 and 47 were vaccinated and unvaccinated, respectively. The vaccination status of the cohort based on gender data indicates that 41 (41%) of all participants were vaccinated males, whereas 12 (12%) were vaccinated females. We found that 42 (42%) were unvaccinated males and 5 (5%) were unvaccinated females. Of 53 vaccinated subjects, 42 and 11 participants were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. Of 47 unvaccinated participants, 28 and 19 were positive and negative for IgG against the SARS-CoV-2 N protein, respectively. The average of S/P “Sample/Positive control” percentages, which correlate to levels of IgG against SARS-CoV-2 N protein, were significantly higher among the vaccinated patients (73.8%) as compared to non-vaccinated patients (57.1%), with p = 0.02. There was a downward trend in levels of IgG against the SARS-CoV-2 N protein with increasing age, except for the 60–69 age group.
References
Sharma A, Tiwari S, Deb M K et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International journal of antimicrobial agents, 2020, 56(2):106054.
Turbett SE et al. Evaluation of three commercial SARS-CoV-2 serologic assays and their performance in two-test algorithms. J.Clin. microbiol. 2020, 59(1):e01892-20.
Mekonnen D et al. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis. Reviews in Medical Virology, 2021, 31(3):e2181.
Sidiq Z, Hanif M, KumarDwivedi K et al. Benefits and limitations of serological assays in COVID-19 infection. Indian Journal of Tuberculosis, 2020.
Coste AT, Jaton K, Papadimitriou-Olivgeris M et al. Comparison of SARS-CoV-2 serological tests with different antigen targets. J Clin Virology, 2021,134:104690.
Poljak M, Valenčak AO, Štamol T et al. Head-to-head comparison of two rapid high-throughput automated electroche-miluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain. J Clin Virology, 2021,137:104784.
Zhang W et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging microbes & infections, 2020, 9(1):386-389.
R. A. Perera et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Eurosurveillance, 2020, 25(16):2000421
Amanat F et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature medicine, 2020, 26(7):1033-1036
Van Elslande J et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect, 2020, 26(11):1557. e1-1557. e7
Okba NM et al. Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerging infectious diseases, 2020, 26(7):1478
Wajnberg A et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months,” Science, 2020, 370(6521):1227-1230.
Deng W et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 2020, 369(6505):818-823.
Alsoussi W B et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J Immun, 2020, 205(4):915-922.
Baraniuk C. How long does covid-19 immunity last? bmj, 2021, 373.
Pradenas E et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med, 2021, 2(3):313-320. e4.
Vickers MA et al. Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. Transfusion, 2021.
Hanrath AT, Payne BA, Duncan CJ. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect, 2021, 82(4):e29-e30.
Hall VJ et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet, 2021, 397(10283):1459-1469.
Chodick G et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA network open, 2021, 4(6):e2115985-e2115985.
Isho B et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science immunology, 2020. 5(52).
Iyer AS et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, Science immunology, 2020, 5(52).
Padoan A et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clinica chimica acta, 2020, 507:164-166.
Secchi M et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. The Journal of clinical investigation, 2020, 130(12).
Wu J et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nature communications, 2021, 12(1):1-9.
Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ et al. Antibody responses in COVID-19: a review. Frontiers in Immunology, 2021, 12.
Dispinseri S et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nature communications, 2021, 12:1-12.
Jalkanen P et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nature communications, 2021, 12(1):1-11.
Kalimuddin S et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med, 2021, 2(6):682-688. e4.
Van Oekelen O et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 2021.
Batra M et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Scientific reports, 2021, 11(1):1-9.
Tian X, Liu L, Jiang W et al. Potent and Persistent Antibody Response in COVID-19 Recovered Patients. Frontiers in immunology, 2021, 12:1986.
den Hartog G et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clinical Infectious Diseases, 2021.
Meyer B. Waning antibodies to SARS-CoV-2–Don’t panic. The Lancet Regional Health–Europe, 2021, 4.
Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection, 2021, 1-15.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19, Cell, 2021.
Naaber P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health-Europe, 2021, p. 100208.
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases, 2020, 20(5):533-534.
Laing ED et al. SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity. medRxiv, 2021.
Bajema KL et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020, JAMA internal medicine, 2021, 181(4):450-460.
Yang HS et al. Association of age with SARS-CoV-2 antibody response. JAMA network open, 2021, 4(3):e214302-e214302.
Tretyn A et al. Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells, 2021, 10(8):1952.
Wheeler SE et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiology Spectrum, 2021, 9(1):e00341-21.
Published
Issue
Section
License
Copyright (c) 2024 A. Donia, M. Nawaz, M.F. Shahid, R. Shahid, A. Javed, T. Yakub, H. Bokhari (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
